SEARCH

SEARCH BY CITATION

References

  • Asherson, R.A. (2006) The catastrophic antiphospholipid (Asherson’s) syndrome. Autoimmunity Reviews, 6, 6467.
  • Banno, F., Kokame, K., Okuda, T., Honda, S., Miyata, S., Kato, H., Tomiyama, Y. & Miyata, T. (2006) Complete deficiency in ADAMTS13 is prothrombotic, but it alone is not sufficient to cause thrombotic thrombocytopenic purpura. Blood, 107, 31613166.
  • Borchiellini, A., Fijnvandraat, K., Ten Cate, J.W., Pajkrt, D., Van Deventer, S.J., Pasterkamp, G., Meijer-Huizinga, F., Zwart-Huinink, L., Voorberg, J. & Van Mourik, J.A. (1996) Quantitative analysis of von Willebrand factor propeptide release in vivo: effect of experimental endotoxemia and administration of 1-deamino-8-D-arginine vasopressin in humans. Blood, 88, 29512958.
  • Crawley, J.T., Lam, J.K., Rance, J.B., Mollica, L.R., O’Donnell, J.S. & Lane, D.A. (2005) Proteolytic inactivation of ADAMTS13 by thrombin and plasmin. Blood, 105, 10851093.
  • Cucnik, S., Kveder, T., Krizaj, I., Rozman, B. & Bozic, B. (2004) High avidity anti-beta 2-glycoprotein I antibodies in patients with antiphospholipid syndrome. Annals of the Rheumatic Diseases, 63, 14781482.
  • Dong, J.F. (2005) Cleavage of ultra-large von Willebrand factor by ADAMTS-13 under flow conditions. Journal of Thrombosis and Haemostasis, 3, 17101716.
  • Ferrari, S., Scheiflinger, F., Rieger, M., Mudde, G., Wolf, M., Coppo, P., Girma, J.P., Azoulay, E., Brun-Buisson, C., Fakhouri, F., Mira, J.P., Oksenhendler, E., Poullin, P., Rondeau, E., Schleinitz, N., Schlemmer, B., Teboul, J.L., Vanhille, P., Vernant, J.P., Meyer, D. & Veyradier, A. (2007) Prognostic value of anti-ADAMTS 13 antibody features (Ig isotype, titer, and inhibitory effect) in a cohort of 35 adult French patients undergoing a first episode of thrombotic microangiopathy with undetectable ADAMTS 13 activity. Blood, 109, 28152822.
  • Furlan, M., Robles, R. & Lamie, B. (1996) Partial purification and characterization of a protease from human plasma cleaving von Willebrand factor to fragments produced by in vivo proteolysis. Blood, 87, 42234234.
  • Furlan, M., Robles, R., Galbusera, M., Remuzzi, G., Kyrle, P.A., Brenner, B., Krause, M., Scharrer, I., Aumann, V., Mittler, U., Solenthaler, M. & Lammle, B. (1998) von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome. New England Journal of Medicine, 339, 15781584.
  • Gerritsen, H.E., Turecek, P.L., Schwarz, H.P., Lammle, B. & Furlan, M. (1999) Assay of von Willebrand factor (vWF)-cleaving protease based on decreased collagen binding affinity of degraded vWF: a tool for the diagnosis of thrombotic thrombocytopenic purpura (TTP). Thrombosis and Haemostasis, 82, 13861389.
  • Groot, E., De Groot, P.G., Fijnheer, R. & Lenting, P.J. (2007) The presence of active von Willebrand factor under various pathological conditions. Current Opinion in Hematology, 14, 284289.
  • Haberichter, S.L., Balistreri, M., Christopherson, P., Morateck, P., Gavazova, S., Bellissimo, D.B., Manco-Johnson, M.J., Gill, J.C. & Montgomery, R.R. (2006) Assay of the von Willebrand factor (VWF) propeptide to identify patients with type 1 von Willebrand disease with decreased VWF survival. Blood, 108, 33443351.
  • Harris, E.N. (1987) Syndrome of the black swan. British Journal of Rheumatology, 26, 324326.
  • Kobayashi, T., Wada, H., Kamikura, Y., Matsumoto, T., Mori, Y., Kaneko, T., Nobori, T., Matsumoto, M., Fujimura, Y. & Shiku, H. (2007) Decreased ADAMTS13 activity in plasma from patients with thrombotic thrombocytopenic purpura. Thrombosis Research, 119, 447452.
  • Kokame, K. & Miyata, T. (2004) Genetic defects leading to hereditary thrombotic thrombocytopenic purpura. Seminars in Hematology, 41, 3440.
  • De Laat, B., Derksen, R.H. & De Groot, P.G. (2006) High-avidity anti-beta glycoprotein I antibodies highly correlate with thrombosis in contrast to low-avidity anti-beta glycoprotein I antibodies. Journal of Thrombosis and Haemostasis, 4, 16191621.
  • Lawrie, A.S., Hoser, M.J. & Savidge, G.F. (1990) Phast assessment of vWf:Ag multimeric distribution. Thrombosis Research, 59, 369373.
  • Lenting, P.J., Westein, E., Terraube, V., Ribba, A.S., Huizinga, E.G., Meyer, D., De Groot, P.G. & Denis, C.V. (2004) An experimental model to study the in vivo survival of von Willebrand factor. Basic aspects and application to the R1205H mutation. Journal of Biological Chemistry, 279, 1210212109.
  • Levine, J.S., Branch, D.W. & Rauch, J. (2002) The antiphospholipid syndrome. New England Journal of Medicine, 346, 752763.
  • Mannucci, P.M., Canciani, M.T., Forza, I., Lussana, F., Lattuada, A. & Rossi, E. (2001) Changes in health and disease of the metalloprotease that cleaves von Willebrand factor. Blood, 98, 27302735.
  • Mannucci, P.M., Vanoli, M., Forza, I., Canciani, M.T. & Scorza, R. (2003) Von Willebrand factor cleaving protease (ADAMTS-13) in 123 patients with connective tissue diseases (systemic lupus erythematosus and systemic sclerosis). Haematologica, 88, 914918.
  • Mannucci, P.M., Capoferri, C. & Canciani, M.T. (2004) Plasma levels of von Willebrand factor regulate ADAMTS-13, its major cleaving protease. British Journal of Haematology, 126, 213218.
  • Miyakis, S., Lockshin, M.D., Atsumi, T., Branch, D.W., Brey, R.L., Cervera, R., Derksen, R.H.W.M., De Groot, PG, Koike, T., Meroni, P.L., Reber, G., Shoenfeld, Y., Tincani, A., Vlachoyiannopoulos, P.G. & Krilis, S.A. (2006) International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). Journal of Thrombosis and Haemostasis, 4, 295306.
  • Moake, J.L. (2002) Thrombotic microangiopathies. New England Journal of Medicine, 347, 589600.
  • Van Mourik, J.A., Boertjes, R., Huisveld, I.A., Fijnvandraat, K., Pajkrt, D., Van Genderen, P.J. & Fijnheer, R. (1999) von Willebrand factor propeptide in vascular disorders: a tool to distinguish between acute and chronic endothelial cell perturbation. Blood, 94, 179185.
  • Nash, M.J., Camilleri, R.S., Kunka, S., Mackie, I.J., Machin, S.J. & Cohen, H. (2004) The anticardiolipin assay is required for sensitive screening for antiphospholipid antibodies. Journal of Thrombosis and Haemostasis, 2, 10771081.
  • Nguyen, T.C., Liu, A., Liu, L., Ball, C., Choi, H., May, W.S., Aboulfatova, K., Bergeron, A.L. & Dong, J.F. (2007) Acquired ADAMTS-13 deficiency in pediatric patients with severe sepsis. Haematologica, 92, 121124.
  • Nossent, A.Y., Van Marion, V., Van Tilburg, N.H., Rosendaal, F.R., Bertina, R.M., Van Mourik, J.A. & Eikenboom, H.C. (2006) von Willebrand factor and its propeptide: the influence of secretion and clearance on protein levels and the risk of venous thrombosis. Journal of Thrombosis and Haemostasis, 4, 25562562.
  • Reiter, R.A., Varadi, K., Turecek, P.L., Jilma, B. & Knobl, P. (2005) Changes in ADAMTS13 (von-Willebrand-factor-cleaving protease) activity after induced release of von Willebrand factor during acute systemic inflammation. Thrombosis and Haemostasis, 93, 554558.
  • Rieger, M., Mannucci, P.M., Kremer Hovinga, J.A., Herzog, A., Gerstenbauer, G., Konetschny, C., Zimmermann, K., Scharrer, I., Peyvandi, F., Galbusera, M., Remuzzi, G., Bohm, M., Plaimauer, B., Lammle, B. & Scheiflinger, F. (2005) ADAMTS13 autoantibodies in patients with thrombotic microangiopathies and other immunomediated diseases. Blood, 106, 12621267.
  • Tsai, H.M. (1996) Physiologic cleavage of von Willebrand factor by a plasma protease is dependent on its conformation and requires calcium ion. Blood, 87, 42354244.
  • Tsai, H.M. & Lian, E.C. (1998) Antibodies to von Willebrand factor-cleaving protease in acute thrombotic thrombocytopenic purpura. New England Journal of Medicine, 339, 15851594.
  • Yamazaki, S., Taki, M., Yasumuro, Y., Takayama, S., Miyake, F., Fujimura, Y. & Suzuki, Y. (2002) [Von Willebrand factor-cleaving protease activity in patients of collagen disease with antiphospholipid antibodies]. Rinsho Byori, 50, 301307.
  • Yarranton, H., Lawrie, A.S., Mackie, I.J., Pinkoski, L., Corash, L. & Machin, S.J. (2005) Coagulation factor levels in cryosupernatant prepared from plasma treated with amotosalen hydrochloride (S-59) and ultraviolet A light. Transfusion, 45, 14531458.